(Q423404)

imported from Wikimedia project

17 November 2015

Tipranavir structure.svg
798 × 313; 39 KB

1 reference

German Wikipedia

mass

602.206±0 dalton

1 reference

2-Pyridinesulfonamide, N-[3-[(1S)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-

Tipranavir (English)

19 October 2016

1 reference

based on heuristic

inferred from InChI

chemical formula

C₃₁H₃₃F₃N₂O₅S

1 reference

Tipranavir (English)

19 November 2016

CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4

1 reference

Tipranavir (English)

19 November 2016

CCC[C@]1(CC(=C(C(=O)O1)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4

1 reference

https://www.whocc.no/atc_ddd_index/?code=J05AE09

Tipranavir (English)

19 November 2016

1 gram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

World Health Organisation international non-proprietary name

tipranavir (English)

1 reference

tipranavir (English)

medical condition treated

19 October 2016

human immunodeficiency virus infectious disease

start time

22 June 2005

approved by

Food and Drug Administration

1 reference

Inxight: Drugs Database

https://drugs.ncats.io/drug/ZZT404XD09

2 November 2018

reference URL

http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf

significant drug interaction

bosentan

1 reference

High-priority drug–drug interactions for use in electronic health records

carbamazepin

1 reference

High-priority drug–drug interactions for use in electronic health records

rifabutin

1 reference

High-priority drug–drug interactions for use in electronic health records

rifampicin

1 reference

High-priority drug–drug interactions for use in electronic health records

rifapentine

1 reference

High-priority drug–drug interactions for use in electronic health records

(RS)-methadone

side effect

withdrawal symptom

1 reference

sourcing circumstances

established

A reference set of clinically relevant adverse drug-drug interactions

atorvastatin

side effect

rhabdomyolysis

1 reference

sourcing circumstances

established

A reference set of clinically relevant adverse drug-drug interactions

atorvastatin

side effect

muscular disease

1 reference

sourcing circumstances

established

A reference set of clinically relevant adverse drug-drug interactions

legal status (medicine)

boxed warning

1 reference

reference URL

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

Australian pregnancy category B3

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category E*

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Tipranavir

last update

1 September 2017

subject has role

HIV protease inhibitors

1 reference

5 March 2018

1 reference

Medical Subject Headings

15 March 2018

1 reference

1 reference

Tipranavir

0 references

catalog

CAS COVID-19 Anti-Viral Candidate Compounds

0 references

Identifiers

InChI

InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1

1 reference

Tipranavir (English)

19 November 2016

2 references

Tipranavir (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

174484-41-4

2 references

Global Substance Registration System

UNII

ZZT404XD09

tipranavir (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=174484-41-4

9 April 2021

1 reference

Tipranavir (English)

19 November 2016

2 references

Tipranavir (English)

19 November 2016

InChIKey

Reaxys registry number

7698323

1 reference

tipranavir (English)

19 October 2016

mapping relation type

2 references

TIPRANAVIR (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1

1 reference

TIPRANAVIR (English)

19 November 2016

2 references

inferred from InChIKey

InChIKey

Hazardous Substances Data Bank

1 reference

1 reference

28 October 2019

Tipranavir (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

InChIKey

DSSTOX compound identifier

0 references

0 references

0 references

ECHA Substance Infocard ID

100.158.066

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.158.066

27 December 2018

N-{3-[(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide (English)

quotation

CAS no.: 174484-41-4 (English)

1 reference